CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents
04 Octobre 2023 - 12:00AM
Business Wire
Decision has No Impact on CareDx’s Ability to
Continue Providing AlloSure® nor Commitment to Transplant
Innovation
CareDx Believes Decision Applies Equally to
Other Diagnostics Patents, including Natera’s Transplant Diagnostic
Patents
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on
the discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers – acknowledges the Supreme Court’s decision
not to review the Federal Circuit’s decision on the patent
eligibility of three Stanford-licensed patents. CareDx notes the
decision does not impact the Company’s ability to continue
providing AlloSure® donor-derived cell-free DNA (dd-cfDNA).
While CareDx respectfully disagrees with the Supreme Court’s
decision, the case law applies equally to other transplant
diagnostics patents, including Natera’s, and CareDx has filed a
motion to invalidate Natera’s patents on these same grounds.
CareDx remains committed to improving transplant patient
outcomes by providing innovative and intelligent solutions
throughout the entire patient journey. It is proud of the
proprietary nature of its ground-breaking quantification method
spurred by years of research and innovation in the field of
transplant diagnostics that led to success where others failed.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a
leading precision medicine solutions company focused on the
discovery, development, and commercialization of clinically
differentiated, high-value healthcare solutions for transplant
patients and caregivers. CareDx offers testing services, products,
and digital healthcare solutions along the pre- and post-transplant
patient journey and is the leading provider of genomics-based
information for transplant patients. For more information, please
visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements related
to CareDx, Inc., including statements regarding the potential
impact created by Supreme Court’s decision (the “Decision”) not to
review CareDx’s case on the eligibility of the three
Stanford-licensed patents (the “Case”), the potential results that
may be achieved by CareDx’s motion filing to invalidate Natera’s
patents (the “Motion”), CareDx’s belief that the case law applies
equally to other transplant diagnostics patents, including Natera’s
(the “Belief”), and the estimated costs of the Case, including
Motion.
These forward-looking statements are based upon information that
is currently available to CareDx and its current expectations,
speak only as of the date hereof, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those projected, including risks related to the Case and
Motion; risks that the Decision may have negative impact on
CareDx’s products, competitive position in the market, royalty
payments, and other patents, risks that CareDx’s motion may not be
granted; risks that CareDx’s Belief may not be accurate; risks that
the Case may take longer or cost more than CareDx expects; general
economic and market factors; and other risks discussed in CareDx’s
filings with the SEC, including the Annual Report on Form 10-K for
the fiscal year ended December 31, 2022 filed by CareDx with the
SEC on February 27, 2023, the quarterly report on Form 10-Q for the
quarter ended March 31, 2023 filed by CareDx with the SEC on May
10, 2023, the quarterly report on Form 10-Q for the quarter ended
June 30, 2023 filed by CareDx with the SEC on August 8, 2023, and
other reports that CareDx has filed with the SEC. Any of these may
cause CareDx’s actual results, performance, or achievements to
differ materially and adversely from those anticipated or implied
by CareDx’s forward-looking statements. CareDx expressly disclaims
any obligation, except as required by law, or undertaking to update
or revise any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231002311825/en/
CareDx, Inc.
Media Relations Anna Czene (818) 731-2203 aczene@CareDx.com
Investor Relations Greg Chodaczek investor@caredx.com
CareDx (NASDAQ:CDNA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
CareDx (NASDAQ:CDNA)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024